
Xandra O. Breakefield, Ph.D.
Professor, Department of Neurology, Harvard Medical School
Geneticist (Neurology), Molecular Neurogenetics Unit, Massachusetts General Hospital
Contact Info
Xandra Breakefield
Massachusetts General Hospital
Building 149
Charlestown, MA, 02129
Mailstop: Rm 6216
Phone: 617-726-5728
Fax: 617-724-1537
breakefield@hms.harvard.edu
Grant Manager
Molecular Neurogenetics Unit
Massachusetts General Hospital
149 13th Street
Charlestown, MA, 02129
Mailstop: #6-6216
Phone: 617-724-6863
Fax: 617-724-1537
sobolewski@helix.mgh.harvard.edu
Massachusetts General Hospital
Building 149
Charlestown, MA, 02129
Mailstop: Rm 6216
Phone: 617-726-5728
Fax: 617-724-1537
breakefield@hms.harvard.edu
Assistant
Robin SobolewskiGrant Manager
Molecular Neurogenetics Unit
Massachusetts General Hospital
149 13th Street
Charlestown, MA, 02129
Mailstop: #6-6216
Phone: 617-724-6863
Fax: 617-724-1537
sobolewski@helix.mgh.harvard.edu
DF/HCC Program Affiliation
Neuro-OncologyResearch Abstract
The Breakefield laboratory is focusing on the use of vector-mediated gene delivery to elucidate the function of proteins underlying hereditary neoplasias associated with neurofibromatosis and tuberous sclerosis, and to test gene therapy for tumors of the nervous system. This work involves development of novel vectors to enhance gene delivery/expression in tumors, and exploration of combined therapeutic modalities, such as pro-drug activation, anti-angiogenesis, and selectively toxic proteins.Publications
- Oehmig A, Cortés ML, Perry KF, Sena-Esteves M, Fraefel C, Breakefield XO.Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector.Gene Ther 2007 Apr 26.
17460718 - Hewett JW, Tannous B, Niland BP, Nery FC, Zeng J, Li Y, Breakefield XO.Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells.Proc Natl Acad Sci U S A 2007 Apr 24;104(17):7271-6.
17428918 - Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO.Treatment of Implantable NF2 Schwannoma Tumor Models with Oncolytic Herpes Simplex Virus G47Delta.Cancer Gene Ther 2007 May;14(5):460-7.
17304235 - Bahn E, Siegert S, Pfander T, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostásy KM.TorsinB expression in the developing human brain.Brain Res 2006 Oct 20;1116(1):112-9.
16938275 - Cortés ML, Oehmig A, Perry KF, Sanford JD, Breakefield XO.Expression of human ATM mutated cDNA in Atm-deficient mouse brain mediated by HSV-1 amplicon vector.Neuroscience 2006 Jun 27.
16809004 - Shah K, Breakefield XO.HSV Amplicon Vectors for Cancer Therapy.Curr Gene Ther 2006 Jun;6(3):361-70.
16787187 - Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO.Metabolic biotinylation of cell surface receptors for in vivo imaging.Nat Methods 2006 May;3(5):391-6.
16628210 - Brown AB, Mahmood U, Cortes ML, Tang Y, Dai G, Stemmer-Rachamimov A, Prabhakar S, Leishear K, Onda H, Kwiatkowski D, Weissleder R, Breakefield X.Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous
16390268 - Aghi M, Kramm CM, Breakefield XO.Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo.J Natl Cancer Inst 1999 Jul 21;91(14):1233-41.
10413425 - Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakefield XO.HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.Hum Gene Ther 1997 Feb 10;8(3):359-70.
9048203




